Home » Newsletters » BioWorld Science

BioWorld Science

May 3, 2019

View Archived Issues

Bragsin inhibits BRAG2-mediated Arf GTPase activation in vitro in a membrane-dependent manner

MIT discovers high-affinity peptide-based PPI inhibitors using noncanonical amino acids

Pericytes rebuild muscle mass

Protecting the brain in sepsis

Melatonin receptor structure solved

Potential chemokine biomarkers for proliferative vitreoretinopathy in primary retinal detachment

Novel dimerizing agent immunoreceptor complex NKG2D-DARIC shows robust in vitro activity

New therapeutic protein reduces B-cell signaling

New gene therapy VTX-803 shows preclinical efficacy for the treatment of PFIC3

Patient recruitment ongoing in phase III study of sitravatinib plus nivolumab in NSCLC

Initiation of first-in-human study of YL-13027 in solid tumors

AMAL Therapeutcs to evaluate ATP-128 plus BI-754091 in phase I study

Cidara Therapeutics presents initial data from phase II STRIVE study of rezafungin

Urinary EGF as a new biomarker of progression of renal disease in children with nephrotic syndrome

Galectin-4 as a novel biomarker in infants with intestinal disease

Samumed launches phase III clinical program for lorecivivint in knee osteoarthritis

Novel LFA-1 antagonist VVN-001 for treating dry eye disease

Phase III study of Trelegy Ellipta in uncontrolled asthma meets primary endpoint

FDA issues second complete response letter for Barhemsys

FDA approves Tibsovo for newly diagnosed IDH1 mutant AML ineligible for intensive chemotherapy

Qternmet XR approved in U.S. for type 2 diabetes

Shanghai De Novo Pharmatech patents adenosine A2A receptor antagonists

Merck & Co. presents indoleamine 2,3-dioxygenase 1 inhibitors

Boehringer Ingelheim identifies new Bruton tyrosine kinase inhibitors

New PTP-2C inhibitors synthesized at REVOLUTION Medicines

Bristol-Myers Squibb discloses new STING agonists

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 15, 2026.
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid
BioWorld
Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...